<a href="https://www.fiercebiotech.com/biotech/eli-lillys-triple-g-drug-drives-deep-weight-loss-phase-3-obesity-trial" hreflang="en">Lilly’s triple-G drug helps patients lose roughly a quarter of weight, showcasing competitive profile</a>
Eli Lilly's triple-G drug, retatrutide, has demonstrated significant weight loss of up to 28.3% in a phase 3 obesity trial, although results fell slightly short of some analysts' high expectations. The drug's efficacy and tolerability position it competitively in the obesity market, with potential FDA approval anticipated later this year.
Eli Lilly's triple hormone receptor agonist, retatrutide, demonstrated significant weight loss in its phase 3 TRIUMPH-1 study, achieving up to 28.3% weight loss after 80 weeks, with further potential as seen in the 29.9% reduction in patients who continued to week 104. Despite some unmet expectations, these results underscore retatrutide's strong standing in the competitive obesity treatment landscape and suggest a forthcoming FDA submission, signaling a potential investment opportunity as Lilly aims to expand its market presence beyond its existing obesity drugs.